Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hiroko, Hayabe"'
Autor:
Tomohisa, Yokoyama, Akiko, Murakoshi, Yui, Kurokawa, Rinako, Kani, Hiroko, Hayabe, Akime, Miyasato, Yoichi, Osato, Hironobu, Miyamatsu, Atsushi, Sofuni, Takao, Itoi, Kimito, Yamada, Norihiko, Ikeda, Makio, Iimori, Kazuma, Ohyashiki
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 39(3)
Few studies have been conducted to elucidate the psychological distress of cancer outpatients being treated with chemotherapy. In this study, we attempted to determine the types of psychological distress endured by cancer outpatients being treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::406616176a342b940d6b509557bd74ab
https://pubmed.ncbi.nlm.nih.gov/22421770
https://pubmed.ncbi.nlm.nih.gov/22421770
Autor:
Yoichi, Osato, Tomohisa, Yokoyama, Yumiko, Saito, Rinako, Kani, Hiroko, Hayabe, Hironobu, Miyamatsu, Kazuma, Ohyashiki
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 38(10)
Vinca alkaloids (VA) are some of the key anti-tumor agents for patients with hematological malignancies, and various adverse events such as paralytic ileus, peripheral neuropathy, and constipation were now recognized as adverse VA effects. Furthermor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::818e73abf0e169d1f83344efc87859a4
https://pubmed.ncbi.nlm.nih.gov/21996963
https://pubmed.ncbi.nlm.nih.gov/21996963
Autor:
Takao Itoi, Hiroko Hayabe, Tomohisa Yokoyama, Akime Miyasato, Norihiko Ikeda, Yoichi Osato, Noriko Gotoh, Tetsuzo Tauchi, Keisuke Miyazawa, Kazuma Ohyashiki, Masaharu Nomura
Publikováno v:
Cancer Research. 72:2904-2904
Nanotechnologies are in development for monitoring drug delivery and therapeutic effect for cancer. However, tumor-targeted multifunctional nanoparticles for imaging of and therapy of lung cancer are not available. The Epidermal growth factor recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd621a5911a8dedf29a316eed6659d20
https://doi.org/10.1158/1538-7445.am2012-2904
https://doi.org/10.1158/1538-7445.am2012-2904
Autor:
Hiroko Hayabe, Yoichi Osato, Akime Miyasato, Tetsuzo Tauchi, Kazuma Ohyashiki, Tomohisa Yokoyama, Takao Akashi, Seiichiro Komatsu
Publikováno v:
Cancer Research. 72:2275-2275
The BCR-ABL tyrosine kinase inhibitor (TKI), imatinib mesylate, has revolutionized the treatment of CML, however, the development of TKI-resistance caused in approximately 10-25% of cases by mutation in the BCR-ABL kinase domain. Therefore, novel the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edb10124cac0b8a3c2fe2c6725e11371
https://doi.org/10.1158/1538-7445.am2012-2275
https://doi.org/10.1158/1538-7445.am2012-2275